Latest broker research reports
with sell recommendations along with share price targets forecast and upside.
Browse thousands of reports and search by company.
Broker Research reports: Sell reports
for all stocks
Wipro reported a flat revenue growth in Q1FY26 owing to decrease in revenue in BFSI and consumer sector. Total bookings and large-deal bookings witnessed an increase in the quarter. However, the revenue guidance for Q2FY26 remains weak. Challenges faced in the macroeconomic environment, discretionary spending and client-specific challenges led to a decrease in revenue from Europe. The company...
Railtel Corporation of India (Railtel) Q1FY26 adjusted net profit grew 2.8% YoY; and as expected revenue growth driven by projects business tends to drive profits slower.
IndusInd Bank's asset quality deteriorate further with GNPA in consumer banking segment inch up to 4.7% vs 4.1% QoQ. MFI portfolio which remains key concern segment reported rise in GNPA (@16% vs 13% QoQ). Credit growth de-grew by 4% YoY (down 3% QoQ); similarly deposit growth de-grew by 3% QoQ. MFI portfolio de-grew by 5% QoQ along with sequential decline in corporate book resulting in 6% QoQ decline in loan growth. We have revised down the credit growth to 8% CAGR (FY25-27) vs 11% earlier. NIMs remain flat at 3.5% vs 3.5% QoQ (if adjusted for one-offs during Q4FY25). Bank reported profit of Rs.6bn vs loss last...
Revenue: For Q1FY26, the revenue increased by 11.4% YoY (+0.5% QoQ) to INR 85,721 Mn, below our estimates by 3.0%, led by weakness in North America, which was partially offset by higher momentum across Europe and the Emerging markets.
Dr. Reddy's (DRRD) Q1FY26 EBITDA adjusted for licensing income was in line with our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from the current level of 15-16% to +21-22% in FY27E. Our FY26 and FY27E EPS broadly remain unchanged. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and competition in...
Tata Technologies has delivered a moderate financial performance in Q1FY26, impacted by uncertain macroeconomic conditions and policy-related pressure on sentiments, resulting in margin compression. Despite these challenges, the company expects a sequential recovery in Q2 and a stronger H2FY26. This optimism is driven by a stronger deal pipeline compared with last year and an early build-up of the order book, which provides increased revenue visibility and...
Not surprisingly, MMFS posted muted results in Q1FY26, with PAT at ~Rs5.3bn largely hit by elevated credit cost (~25bps higher than our estimate of ~1.9% of business assets), and YoY AUM growth of 15%/disbursement growth of only 1%.
